Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Conditions
Cervical Adenocarcinoma - Cervical Adenosquamous Carcinoma - Cervical Squamous Cell Carcinoma - Recurrent Cervical Carcinoma - Stage IVA Cervical Cancer - Stage IVB Cervical Cancer
Conditions: official terms
Adenocarcinoma - Carcinoma - Carcinoma, Adenosquamous - Carcinoma, Squamous Cell - Uterine Cervical Neoplasms
Study Type
Interventional
Study Phase
Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Laboratory Biomarker Analysis Type: Other
Name: Nivolumab Type: Biological
Overall Status
Recruiting
Summary
This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
Detailed Description
PRIMARY OBJECTIVES:

I. To assess the antitumor activity (proportion of objective response by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) of nivolumab with objective tumor response in patients with persistent, recurrent or metastatic carcinoma of the cervix.

II. To determine the nature and degree of toxicity of nivolumab as assessed by Common Terminology Criteria for Adverse Events (CTCAE) in patients with persistent, recurrent or metastatic carcinoma of the cervix.

SECONDARY OBJECTIVES:

I. To estimate the duration of progression-free survival (PFS) and overall survival (OS).

TERTIARY OBJECTIVES:

I. To systematically evaluate programmed cell death (PD)-1 and B7 homolog 1 (B7-H1) (i.e., PD-1 ligand) expression in tumor infiltrating lymphocytes (TILs) and cervical cancer cells and explore their correlations with objective response, PFS, and OS in nivolumab-treated patients with PD-1 and B7-H1 scoring results.

II. To explore the composition of immune infiltrates in tumor specimens/biopsies from primary and/or metastatic/recurrent sites with selected markers including (but not limited) to cluster of differentiation (CD)4+,CD8+, forkhead box P3 (FoxP3), CD25, lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin mucin-3 (TIM-3), and inducible T-cell co-stimulator (ICOS) and their correlations to objective response, PFS and OS in nivolumab-treated patients.

III. To evaluate human papillomavirus (HPV) status and to explore the changes of pre- and post-immune therapy responses to HPV16/18/31/35/45 E7 antigens in patients peripheral blood lymphocytes (PBL) and serum using proliferative and interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) (cellular immunity) and serological (enzyme-linked immunosorbent assay [ELISA]) assays.

IV. To explore the levels of circulating tumor cells (CTCs) pre-treatment and at 8 and 12 weeks and their association with patient outcome.

OUTLINE:

Patients receive nivolumab intravenously (IV) over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Patients must have persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix with documented disease progression (disease not amendable to curative therapy); histologic confirmation of the original primary tumor is required via the pathology report

- All patents must have measurable disease as defined by RECIST 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI

- Patients must have at least one "target" lesion" to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy

- Appropriate for study entry based on the following diagnostic workup:

- History/physical examination within 28 days prior to registration

- Imaging of target lesion(s) within 28 days prior to registration

- Further protocol-specific assessments:

- Recovery from adverse effects of recent surgery, radiotherapy or chemotherapy

- Any other prior therapy directed at the malignant tumor including chemotherapy, biologic/targeted agents and immunologic agents must be discontinued at least three weeks prior to registration

- Investigation agents must be discontinued for at least 30 days prior to registration

- Any prior radiation therapy must be completed at least 4 weeks prior to registration

- At least 4 weeks must have elapsed since any major surgery prior to registration

- Patients must have had one prior systemic chemotherapeutic regimen for management of persistent, recurrent or metastatic carcinoma of the cervix (e.g.; paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab); chemotherapy administered concurrent with primary radiation (e.g.; weekly cisplatin) is not counted as a systemic chemotherapy regimen; adjuvant chemotherapy given following the completion of radiation therapy (or concurrent chemotherapy and radiation therapy) is not counted as a systemic chemotherapy regimen (e.g.; paclitaxel and carboplatin for up to 4 cycles); NOTE: patients who have received more than one prior regimen are NOT eligible

- Performance status of 0 or 1

- Absolute neutrophil count (ANC) >= 1,500/ul

- Platelets >= 100,000/ul

- Creatinine =< 1.5 x institutional upper limit of normal (ULN) or creatinine clearance (CrCl) >= 40 mL/min using Cockcroft-Gault formula

- Bilirubin =< 1.5 x ULN

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN

- Normal thyroid function testing (thyroid stimulating hormone [TSH]) within 14 days prior to registration

- The patient or a legally authorized representative must provide study-specific informed consent authorization permitting release of personal health information prior to study entry

Exclusion Criteria:

- Patients who have had prior therapy with nivolumab or with an anti-PD-1, anti-PD-ligand (L)1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune check point pathways

- History of severe hypersensitivity reaction to any monoclonal antibody

- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years

- Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure and unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- Patients who are pregnant or nursing; women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug; WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IV/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab; women must not be breastfeeding

- Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile or have undergone definitive radiation) do not require contraception

- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy of bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 month amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level greater than 40 mIU/mL

- WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product

- Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform the treating physician immediately

- Patients with known brain metastases or leptomeningeal metastases are excluded unless the following conditions are met:

- Metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for at least 4 weeks after treatment is complete (must be confirmed within 28 days prior to the first dose of nivolumab administration)

- There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration

- Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)

- Patients should be excluded if they have a positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection

- Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IRB), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded; patient with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible; patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible

- NOTE: patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)

- Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted

- Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, abdominal/pelvic fistula, gastrointestinal perforation, gastrointestinal (GI) obstruction and/or who require parenteral hydration and/or nutrition
Locations
Sutter Auburn Faith Hospital
Auburn, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Mills - Peninsula Hospitals
Burlingame, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Eden Hospital Medical Center
Castro Valley, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Sutter Davis Hospital
Davis, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Memorial Medical Center
Modesto, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Palo Alto Medical Foundation-Camino Division
Mountain View, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Palo Alto Medical Foundation Health Care
Palo Alto, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Sutter Roseville Medical Center
Roseville, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Sutter General Hospital
Sacramento, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
California Pacific Medical Center-Pacific Campus
San Francisco, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Sutter Pacific Medical Foundation
Santa Rosa, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Palo Atlo Medical Foundation-Sunnyvale
Sunnyvale, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Sutter Cancer Centers Radiation Oncology Services-Vacaville
Vacaville, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Sutter Solano Medical Center/Cancer Center
Vallejo, California, United States
Status: Recruiting
Contact: Stacy D. D'Andre - 415-209-2686 - bernicl@sutterhealth.org
Yale University
New Haven, Connecticut, United States
Status: Recruiting
Contact: Alessandro D. Santin - 203-785-5702
Beebe Medical Center
Lewes, Delaware, United States
Status: Recruiting
Contact: Gregory A. Masters - 302-733-6227
Christiana Care Health System-Christiana Hospital
Newark, Delaware, United States
Status: Recruiting
Contact: Gregory A. Masters - 302-733-6227
Christiana Gynecologic Oncology LLC
Newark, Delaware, United States
Status: Recruiting
Contact: Gregory A. Masters - 302-733-6227
Delaware Clinical and Laboratory Physicians PA
Newark, Delaware, United States
Status: Recruiting
Contact: Gregory A. Masters - 302-733-6227
Helen F Graham Cancer Center
Newark, Delaware, United States
Status: Recruiting
Contact: Gregory A. Masters - 302-733-6227
Medical Oncology Hematology Consultants PA
Newark, Delaware, United States
Status: Recruiting
Contact: Gregory A. Masters - 302-733-6227
Regional Hematology and Oncology PA
Newark, Delaware, United States
Status: Recruiting
Contact: Gregory A. Masters - 302-733-6227
Beebe Health Campus
Rehoboth Beach, Delaware, United States
Status: Recruiting
Contact: Gregory A. Masters - 302-733-6227
Nanticoke Memorial Hospital
Seaford, Delaware, United States
Status: Recruiting
Contact: Gregory A. Masters - 302-733-6227
Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware, United States
Status: Recruiting
Contact: Gregory A. Masters - 302-733-6227
Northwestern University
Chicago, Illinois, United States
Status: Recruiting
Contact: Emily Berry - 312-695-1301 - cancer@northwestern.edu
Good Samaritan Regional Health Center
Mount Vernon, Illinois, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Mercy Cancer Center-West Lakes
Clive, Iowa, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Alegent Health Mercy Hospital
Council Bluffs, Iowa, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Mercy Medical Center - Des Moines
Des Moines, Iowa, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Mercy Medical Center-West Lakes
West Des Moines, Iowa, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Flaget Memorial Hospital
Bardstown, Kentucky, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Commonwealth Cancer Center-Corbin
Corbin, Kentucky, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Saint Joseph Hospital East
Lexington, Kentucky, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Saint Joseph Radiation Oncology Resource Center
Lexington, Kentucky, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Jewish Hospital
Louisville, Kentucky, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Jewish Hospital Medical Center Northeast
Louisville, Kentucky, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Saints Mary and Elizabeth Hospital
Louisville, Kentucky, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Jewish Hospital Medical Center South
Shepherdsville, Kentucky, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Status: Recruiting
Contact: Robert T. Morris - 313-576-9363
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, United States
Status: Recruiting
Contact: Robert T. Morris - 313-576-9363
Central Care Cancer Center-Carrie J Babb Cancer Center
Bolivar, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
CoxHealth Cancer Center
Branson, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Freeman Health System
Joplin, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Mercy Hospital-Joplin
Joplin, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Phelps County Regional Medical Center
Rolla, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Saint John's Clinic-Rolla-Cancer and Hematology
Rolla, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Mercy Hospital Saint Louis
Saint Louis, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Saint Louis Cancer and Breast Institute-South City
Saint Louis, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
CoxHealth South Hospital
Springfield, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
Mercy Hospital Springfield
Springfield, Missouri, United States
Status: Recruiting
Contact: Jay W. Carlson - 800-821-7532
CHI Health Saint Francis
Grand Island, Nebraska, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
CHI Health Good Samaritan
Kearney, Nebraska, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Heartland Hematology and Oncology
Kearney, Nebraska, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Saint Elizabeth Regional Medical Center
Lincoln, Nebraska, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Alegent Health Immanuel Medical Center
Omaha, Nebraska, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Alegent Health Lakeside Hospital
Omaha, Nebraska, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Creighton University Medical Center
Omaha, Nebraska, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Hemotology and Oncology Consultants PC
Omaha, Nebraska, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Midlands Community Hospital
Papillion, Nebraska, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Women's Cancer Center of Nevada
Las Vegas, Nevada, United States
Status: Recruiting
Contact: Nicola M. Spirtos - 702-851-4672
Hackensack University Medical Center
Hackensack, New Jersey, United States
Status: Recruiting
Contact: Donna T. McNamara - 201-996-2879
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Status: Recruiting
Contact: Carol Aghajanian - 212-639-7202
Sampson Radiation Oncology
Clinton, North Carolina, United States
Status: Terminated
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, United States
Status: Recruiting
Contact: James N. Atkins - 919-580-0000
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, United States
Status: Recruiting
Contact: James N. Atkins - 919-580-0000
Wayne Memorial Hospital
Goldsboro, North Carolina, United States
Status: Recruiting
Contact: James N. Atkins - 919-580-0000
Wayne Radiation Oncology
Goldsboro, North Carolina, United States
Status: Terminated
Onslow Memorial Hospital
Jacksonville, North Carolina, United States
Status: Recruiting
Contact: James N. Atkins - 919-580-0000
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina, United States
Status: Recruiting
Contact: James N. Atkins - 919-580-0000
Southeastern Medical Oncology Center-Wilson
Wilson, North Carolina, United States
Status: Recruiting
Contact: James N. Atkins - 919-580-0000
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, United States
Status: Recruiting
Contact: Steven E. Waggoner - 800-641-2422
Bethesda North Hospital
Cincinnati, Ohio, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Good Samaritan Hospital - Cincinnati
Cincinnati, Ohio, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
TriHealth Cancer Institute-Anderson
Cincinnati, Ohio, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
TriHealth Cancer Institute-Westside
Cincinnati, Ohio, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Case Western Reserve University
Cleveland, Ohio, United States
Status: Recruiting
Contact: Steven E. Waggoner - 800-641-2422
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio, United States
Status: Recruiting
Contact: Peter G. Rose - 866-223-8100
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Status: Recruiting
Contact: Peter G. Rose - 866-223-8100
Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio, United States
Status: Recruiting
Contact: Peter G. Rose - 866-223-8100
Ireland Cancer Center Landerbrook Health Center
Mayfield Heights, Ohio, United States
Status: Recruiting
Contact: Steven E. Waggoner - 800-641-2422
Lake University Ireland Cancer Center
Mentor, Ohio, United States
Status: Recruiting
Contact: Steven E. Waggoner - 800-641-2422
University Hospitals Sharon Health Center
Wadsworth, Ohio, United States
Status: Recruiting
Contact: Steven E. Waggoner - 800-641-2422
UHHS-Westlake Medical Center
Westlake, Ohio, United States
Status: Recruiting
Contact: Steven E. Waggoner - 800-641-2422
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Status: Recruiting
Contact: Robert S. Mannel - 405-271-4272 - julie-traylor@ouhsc.edu
Tulsa Cancer Institute
Tulsa, Oklahoma, United States
Status: Recruiting
Contact: Robert S. Mannel - 405-271-4272 - julie-traylor@ouhsc.edu
Abington Memorial Hospital
Abington, Pennsylvania, United States
Status: Recruiting
Contact: Parviz Hanjani - 215-481-2402
Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania, United States
Status: Recruiting
Contact: Gregory A. Masters - 302-733-6227
Ephrata Cancer Center
Ephrata, Pennsylvania, United States
Status: Recruiting
Contact: Mark A. Miller - 877-441-7957
Adams Cancer Center
Gettysburg, Pennsylvania, United States
Status: Recruiting
Contact: Mark A. Miller - 877-441-7957
Cherry Tree Cancer Center
Hanover, Pennsylvania, United States
Status: Recruiting
Contact: Mark A. Miller - 877-441-7957
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Status: Recruiting
Contact: Mark A. Morgan - 800-474-9892
WellSpan Health-York Cancer Center
York, Pennsylvania, United States
Status: Recruiting
Contact: Mark A. Miller - 877-441-7957
WellSpan Health-York Hospital
York, Pennsylvania, United States
Status: Recruiting
Contact: Mark A. Miller - 877-441-7957
Women and Infants Hospital
Providence, Rhode Island, United States
Status: Recruiting
Contact: Paul A. DiSilvestro - 401-274-1122
Greenville Health System Cancer Institute-Easley
Easley, South Carolina, United States
Status: Recruiting
Contact: Jeffrey W. Elder - 864-679-3966
Greenville Health System Cancer Institute-Andrews
Greenville, South Carolina, United States
Status: Recruiting
Contact: Jeffrey W. Elder - 864-679-3966
Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina, United States
Status: Recruiting
Contact: Jeffrey W. Elder - 864-679-3966
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, United States
Status: Recruiting
Contact: Jeffrey W. Elder - 864-679-3966
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, United States
Status: Recruiting
Contact: Jeffrey W. Elder - 864-679-3966
Greenville Memorial Hospital
Greenville, South Carolina, United States
Status: Recruiting
Contact: Jeffrey W. Elder - 864-679-3966
Saint Francis Cancer Center
Greenville, South Carolina, United States
Status: Recruiting
Contact: David Griffin - 864-512-1000
Saint Francis Hospital
Greenville, South Carolina, United States
Status: Recruiting
Contact: David Griffin - 864-512-1000
Greenville Health System Cancer Institute-Greer
Greer, South Carolina, United States
Status: Recruiting
Contact: Jeffrey W. Elder - 864-679-3966
Greenville Health System Cancer Institute-Seneca
Seneca, South Carolina, United States
Status: Recruiting
Contact: Jeffrey W. Elder - 864-679-3966
Greenville Health System Cancer Institute-Spartanburg
Spartanburg, South Carolina, United States
Status: Recruiting
Contact: Jeffrey W. Elder - 864-679-3966
Memorial Hospital
Chattanooga, Tennessee, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Pulmonary Medicine Center of Chattanooga-Hixson
Hixson, Tennessee, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Memorial GYN Plus
Ooltewah, Tennessee, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Harrison Medical Center
Bremerton, Washington, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Highline Medical Center-Main Campus
Burien, Washington, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Saint Elizabeth Hospital
Enumclaw, Washington, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Saint Francis Hospital
Federal Way, Washington, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Saint Clare Hospital
Lakewood, Washington, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Harrison HealthPartners Hematology and Oncology-Poulsbo
Poulsbo, Washington, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
Status: Recruiting
Contact: Heidi J. Gray - 206-616-8289
Northwest Hospital
Seattle, Washington, United States
Status: Recruiting
Contact: Heidi J. Gray - 206-616-8289
Seattle Cancer Care Alliance
Seattle, Washington, United States
Status: Recruiting
Contact: Heidi J. Gray - 206-616-8289
University of Washington Medical Center
Seattle, Washington, United States
Status: Recruiting
Contact: Heidi J. Gray - 206-616-8289
Women's Cancer Center of Seattle
Seattle, Washington, United States
Status: Recruiting
Contact: Heidi J. Gray - 206-616-8289
Franciscan Research Center-Northwest Medical Plaza
Tacoma, Washington, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Northwest Medical Specialties PLLC
Tacoma, Washington, United States
Status: Recruiting
Contact: Mehmet S. Copur - 800-998-2119
Start Date
May 2015
Sponsors
National Cancer Institute (NCI)
Source
National Cancer Institute (NCI)
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page